Expression of PD-L1 was reported to be correlated with poor clinical outcomes in a number of human cancers, including lung, melanoma, breast, bladder, ovarian, pancreatic, esophageal adenocarcinoma, and kidney tumors [25]. This evidence concerns the gene CD274 and esophageal adenocarcinoma.